Diabetes

NEW YORK — The American Diabetes Association, partnering with Walgreens and Duane Reade, on Tuesday kicked off its 25th Annual American Diabetes Association Alert Day, a one-day "wake-up call" asking the American public to take the Diabetes Risk Test to find out if they are at risk for developing Type 2 diabetes.   

ATLANTA — The percentage of people who are at risk of developing Type 2 diabetes and aware of it has risen slightly over the past few years, but remains low, according to a report by the Centers for Disease Control and Prevention.

RIDGEFIELD, Conn. — Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said Monday.

BI and Lilly announced the submission of a regulatory application to the Food and Drug Administration for empagliflozin. The drug belongs to a new drug class known as SGLT2 inhibitors, which work by removing excess glucose through the urine by blocking its reabsorption in the kidneys. The companies are testing the drug in a late-stage clinical trial for which they plan to enroll 14,500 patients.

MILPITAS, Calif. — LifeScan on Monday initiated a voluntary recall and replacement for all of its OneTouch VerioIQ blood-glucose meters in the United States, effective immediately.

BAGSVÆRD, Denmark — A drug made by Novo Nordisk for Type 2 diabetes produced a 6% loss of weight in a trial of the drug in obese patients, the company said.

The Danish drug maker announced results of a 56-week phase-3 trial to investigate the potential of Victoza (liraglutide) to produce and maintain weight loss in overweight and obese patients with Type 2 diabetes.

PITTSBURGH — Mylan has settled a patent-infringement lawsuit filed by Shionogi over its generic version of a drug for diabetes, Mylan said.

The generic drug maker said that under the agreement, it can launch a generic version of Shionogi's Fortamet (metformin hydrochloride) extended-release tablets in the 500-mg and 1,000-mg strengths on Aug. 1.

Metformin hydrochloride extended-release tablets in those two strengths had sales of about $125 million during the 12-month period that ended in September, according to IMS Health.

CALABASH, N.C. — It seems that Fluffy is getting a little fluffy as a new survey indicates that pet obesity is on the rise, particularly among cats.

The Association for Pet Obesity Prevention found in its sixth annual National Pet Obesity Awareness Day survey that 52.5% of dogs and 58.3% of cats were overweight or obese, meaning that about 80 million dogs and cats are at increased risk for weight-related disorders such as diabetes, osteoarthritis, high blood pressure and cancers. The survey included 1,485 dogs and 450 cats.

Sales of glucose meters were slightly up over the holidays, reaching $67.7 million for the 12 weeks ended Dec. 30 across U.S. multi-outlets, according to SymphonyIRI Group data.

With a new diabetes diagnosis being made once every 21 seconds, coupled with the coming expansion of Medicaid requirements across at least some states, there will be a significant consumer demand for blood-glucose meters and the test strips that supply them for some time to come.